NO976122D0 - AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes - Google Patents

AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes

Info

Publication number
NO976122D0
NO976122D0 NO976122A NO976122A NO976122D0 NO 976122 D0 NO976122 D0 NO 976122D0 NO 976122 A NO976122 A NO 976122A NO 976122 A NO976122 A NO 976122A NO 976122 D0 NO976122 D0 NO 976122D0
Authority
NO
Norway
Prior art keywords
antibody
fas ligand
fas
apoptosis
assay method
Prior art date
Application number
NO976122A
Other languages
English (en)
Other versions
NO324120B1 (no
NO976122L (no
Inventor
Kamon Shirakawa
Tomokazu Matsusue
Shigekazu Nagata
Man Sung Co
Maximiliano Vasquez
Original Assignee
Mochida Pharm Co Ltd
Osaka Bioscience Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/649,100 external-priority patent/US6114507A/en
Application filed by Mochida Pharm Co Ltd, Osaka Bioscience Inst filed Critical Mochida Pharm Co Ltd
Publication of NO976122D0 publication Critical patent/NO976122D0/no
Publication of NO976122L publication Critical patent/NO976122L/no
Publication of NO324120B1 publication Critical patent/NO324120B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
NO19976122A 1995-06-30 1997-12-29 Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene. NO324120B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18848095 1995-06-30
US08/649,100 US6114507A (en) 1995-06-30 1996-05-17 Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
PCT/JP1996/001820 WO1997002290A1 (fr) 1995-06-30 1996-07-01 ANTICORPS DE LIGAND ANTIFas ET PROCEDE D'EPREUVE LE FAISANT INTERVENIR

Publications (3)

Publication Number Publication Date
NO976122D0 true NO976122D0 (no) 1997-12-29
NO976122L NO976122L (no) 1998-02-27
NO324120B1 NO324120B1 (no) 2007-08-27

Family

ID=26504954

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19976122A NO324120B1 (no) 1995-06-30 1997-12-29 Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene.

Country Status (8)

Country Link
EP (1) EP0842948B1 (no)
JP (1) JP3925663B2 (no)
CN (1) CN1196733A (no)
AU (1) AU724856B2 (no)
CA (1) CA2225852C (no)
NO (1) NO324120B1 (no)
NZ (1) NZ311174A (no)
WO (1) WO1997002290A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1642908A2 (en) 1996-09-02 2006-04-05 Okumura, Ko Apoptosis-induced site from fas ligand
US5858990A (en) * 1997-03-04 1999-01-12 St. Elizabeth's Medical Center Fas ligand compositions for treatment of proliferative disorders
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
US6905684B1 (en) 1997-11-10 2005-06-14 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung diseases
CA2319421A1 (en) 1998-02-06 1999-08-12 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for inflammatory intestinal disease
DE69935976D1 (de) * 1998-05-14 2007-06-14 Mochida Pharm Co Ltd Prävention und therapie von leberzirrhosen
CA2333880A1 (en) 1998-05-29 1999-12-09 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for autoimmune demyelinating diseases
JP4734739B2 (ja) * 2000-09-29 2011-07-27 東レ株式会社 哺乳動物のガン抑制方法
PT1490405E (pt) * 2002-03-21 2007-11-07 Lilly Co Eli Anticorpos humanos anti-ligando de hfas antagonistas e fragmentos dos mesmos
US7371383B2 (en) * 2002-04-12 2008-05-13 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
PL211180B1 (pl) * 2002-12-17 2012-04-30 Merck Patent Gmbh Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
KR101224235B1 (ko) * 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
WO2005012363A1 (ja) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. 標的化された炎症惹起剤
AU2007341631B9 (en) 2006-12-28 2012-10-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
EP2376536B1 (en) 2008-12-12 2015-02-25 Pincell Srl Remedies for pemphigus containing anti fas ligand antibodies
BRPI0820877A2 (pt) * 2007-12-12 2017-06-06 Pincell Srl remédios para pênfigo contendo anticorpos ligantes anti faz
EP2246426A4 (en) 2008-01-29 2011-08-10 Inst Antibodies Co Ltd COMPOSITION FOR NEUTRALIZING BOTULINUM TOXIN TYPE A AND ANTI-TOXIN BOTULINUM HUMAN ANTIBODY TYPE A
US11369572B2 (en) * 2009-07-21 2022-06-28 Queen Mary & Westfield College Fas (Apo-1,CD95) targeted platforms for intracellular drug delivery
JO3437B1 (ar) * 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
RU2744836C2 (ru) * 2014-05-08 2021-03-16 Новодиакс, Инк. Прямой иммуногистохимический анализ
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
CN108290950B (zh) 2015-09-23 2022-01-28 阿珀吉科吉尼科斯股份公司 抗cd95l抗体
EP3592392B1 (en) * 2017-03-10 2023-09-13 University of Louisville Research Foundation, Inc. Fasl-engineered biomaterials with immunomodulatory function
CN116888257A (zh) * 2022-01-21 2023-10-13 北京三诺佳邑生物技术有限责任公司 特异性识别FasL的抗体及其应用
WO2023208990A1 (en) 2022-04-26 2023-11-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist,

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0723556A4 (en) 1993-10-14 2003-03-19 Immunex Corp FAS ANTAGONISTS AND THEIR APPLICATIONS
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
ATE387458T1 (de) * 1994-01-07 2008-03-15 Mochida Pharm Co Ltd Fas-antigenbindender ligand
AU716731B2 (en) 1995-03-20 2000-03-02 Ko Okumura Monoclonal antibody reacting specifically with Fas ligand and process for producing the same

Also Published As

Publication number Publication date
CN1196733A (zh) 1998-10-21
JP3925663B2 (ja) 2007-06-06
AU6243596A (en) 1997-02-05
EP0842948A4 (en) 2004-12-15
WO1997002290A1 (fr) 1997-01-23
NO324120B1 (no) 2007-08-27
EP0842948B1 (en) 2009-04-22
AU724856B2 (en) 2000-10-05
NZ311174A (en) 1999-04-29
NO976122L (no) 1998-02-27
CA2225852A1 (en) 1997-01-23
EP0842948A1 (en) 1998-05-20
CA2225852C (en) 2009-04-14

Similar Documents

Publication Publication Date Title
NO976122D0 (no) AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes
Plotz et al. Assignment of direct and facilitated hemolytic plaques in mice to specific immunoglobulin classes
DE69318420D1 (de) Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
ATE175241T1 (de) Antikörper gegen alpha v beta 3 integrin
JP2003534781A5 (no)
BRPI0415565A (pt) anticorpos que aresentam uma taxa de fucose e de galactose otimizada
DE69637909D1 (de) ANTI-Fas-LIGAND ANTIKÖRPER UND TESTMETHODE UNTER VERWENDUNG DERSELBEN
ES2113891T3 (es) Anticuerpos monoclonales de raton.
FI964845A (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
Lesley et al. Antigen receptor molecules: inhibition by antiserum against kappa light chains
Zhang et al. Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes.
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
SE8300320D0 (sv) Monoclonal antibody formulation for diagnostic use
Sulica et al. Effect of protein A of Staphylococcus aureus on the binding of monomeric and polymeric IgG to Fc receptor-bearing cells.
Martens et al. Increased circulating interleukin‐6 (IL‐6) activity in endotoxin‐challenged mice pretreated with anti‐IL‐6 antibody is due to IL‐6 accumulated in antigen‐antibody complexes
DE69018968T2 (de) BLUTGERINNUNGSFAKTOR BETA XIIa MONOKLONALE ANTIKÖRPER UND IMMUNANALYSE.
ATE58172T1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
Ezzatifar et al. Large scale generation and characterization of anti-human IgA monoclonal antibody in ascitic fluid of BALB/c mice
DE2853453C2 (no)
ID20117A (id) Antibodi anti-fas
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
ATE178074T1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
Bjerner Human anti‐immunoglobulin antibodies interfering in immunometric assays
EP0143367A3 (en) Method for production of monoclonal antibodies for cancer diagnosis and therapy